Anti-Mouse CD134 (Clone OX-86) – PE

Anti-Mouse CD134 (Clone OX-86) – PE

Product No.: C867

[product_table name="All Top" skus="C392"]

- -
- -
Clone
OX-86
Target
CD134
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
OX-40, TNFRSF4, ACT35
Isotype
IgG1 κ
Applications
FC

- -
- -
Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Mouse
Host Species
Rat
Product Concentration
0.2 mg/ml
Formulation
This R-phycoerythrin (R-PE) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Storage and Handling
This R-phycoerythrin (R-PE) conjugate is stable when stored at 2-8°C. Do not freeze.
Country of Origin
USA
Shipping
Next Day 2-8°C
Excitation Laser
Blue Laser (488 nm) and/or Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Additional Applications Reported In Literature ?
FC
IHC
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
Clone OX-86 reacts with murine CD134 (OX-40, TNFRSF4).
Antigen Distribution
CD134 is expressed on activated CD4 and CD8 T cells, activated regulatory T cells, B cells, NKT cells, NK cells, and neutrophils.
Background
CD134 functions as an important immune checkpoint, and its depletion in murine mouse models demonstrate that lack of CD134 expression leads to reduced CD4+ and CD8+ T cells1. When CD134 is bound by its corresponding ligand (OX-40L), an optimal T cell response is generated and plays a significant role in determining the amount of memory T-cells remaining after the immune response1. CD134 has also been found to play an important role in carcinogenesis, as treatment with activating in vivo antibodies against CD134 enhanced tumor growth, suggesting that CD134 is an important tumor suppressor, and its absence disrupts the immune response to tumors2,3.

Antigen Details

Research Area
Immunology

References & Citations

1. Redmond WL, Ruby CE, Weinberg AD. Crit Rev Immunol. 29(3):187-201. 2019
2. Morris A, Vetto JT, Ramstad T, et. al. Breast Cancer Res Treat. 67: 71–80. 2001.
3. Weinberg AD, Rivera MM, Prell R, et. al. J Immunol. 164: 2160–9. 2000.
4. al-Shamkhani A, Birkeland ML, Puklavec M, et. al. Eur J Immunol. Aug;26(8):1695-9. 1996.
5. Higgins LM, McDonald SA, Whittle N, et. al. J Immunol. Jan 1;162(1):486-93. 1999.
Flow Cytometry
- -
- -

Formats Available

- -
- -
Products are for research use only. Not for use in diagnostic or therapeutic procedures.